CN Mobile Logo


ASCO 2014 Lung Cancer

ASCO 2014 Lung Cancer

Dr. Aisner discusses some of the key ways oncologists can work better with pathologists at their institutions.

From the 2014 ASCO Annual Meeting, this internationally renowned lung cancer expert discusses oncogenic driver mutations in lung cancer.

Cisplatin, etoposide, and irinotecan outperformed topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC) in a Japanese trial, though there was substantially increased toxicity with the regimen.

This slide show highlights some of the top studies and news on lung cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.

The addition of ramucirumab to docetaxel improved outcomes over placebo with docetaxel as a second-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), according to results of the REVEL trial.

The addition of bevacizumab to erlotinib as first-line therapy yielded a significantly extended progression-free survival in patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to a new phase II study.

The addition of the anti-EGFR antibody necitumumab to gemcitabine-cisplatin chemotherapy resulted in a modest but significant benefit to patients with stage IV squamous cell non-small-cell lung cancer, according to results of the SQUIRE study presented at ASCO.


Subscribe to ASCO 2014 Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.